Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
A series of analogues of the delta opioid receptor antagonist naltrindole (1) possessing a phenyl, phenoxy, or benzyloxy group at the 4'-, 5'-, 6'-, or - 7'-positions (4-15) and a 2-(2-pyridinyl)ethenyl group at the 5'-position (16) on the indolic benzene ring were synthesized through Fischer indolization of naltrexone. Compounds 4-16 were evaluated for their affinities in opioid receptor binding assays in rat or guinea pig brain membranes and for their opioid antagonist and agonist activities in vitro on the guinea pig ileum (GPI) and mouse vas deferens (MVD) preparations. All of the compounds displayed delta selectivity in binding to the delta, mu, and kappa opioid receptors. The binding potencies of most of the compounds at the delta, mu, and kappa sites, however, were lower than that of 1. Among positional isomers, the 7'-substituted compounds in general had higher affinities than 6'-, 5'-, or 4'-substituted analogues, indicating that bulky groups are tolerated better at the 7'-position than at other positions. The affinity of the compounds were also determined at putative subtypes of the delta and kappa receptors: deltacx-1 (mu-like), deltacx-2 (delta-like), and the kappa2b site in an attempt to identify subtype selective agents. Although none were identified, the data revealed a different rank-order of potency beteween mu vs deltacx-1, deltacx-2 vs delta, and the kappa2b vs mu, delta, and kappa1. The antagonist potencies of the compounds in the MVD were in agreement with their binding affinities at the delta site in rat brain membrane. The most potent member of the series, the 7'-phenoxy compound 14, binds to the delta site with a Ki of 0.71 nM, shows >40-fold delta over mu and delta over kappa binding selectivity, and exhibits delta receptor antagonist potency in the MVD with a Ke of 0.25 nM, properties which are comparable to the delta receptor affinity and antagonist potency of naltrindole (Ki = 0.29 nM, Ke = 0. 49 nM). Interestingly, many members of the series were found to possess significant partial to full agonist activities in the MVD (6, 9, 10, 13, 16) or GPI (6, 11, 14, 15). Among the compounds studied, the highest agonist activity in the MVD was displayed by 16 (IC50 = 220 nM), and the highest agonist activity in the GPI was displayed by 14 (IC50 = 450 nM). The overall affinity and activity profile of compound 14 is, therefore, that of a nonpeptide ligand possessing mixed mu agonist/delta antagonist properties. Recently there has been considerable interest in such compounds possessing mu agonist/delta antagonist activities because of their potential therapeutic usefulness as analgesics with low propensity to produce tolerance and dependence side effects. The results of the present study suggest that morphinan derivatives related to 16 and 14 may provide useful leads for the development of potent nonpeptide ligands possessing delta agonist or mixed delta antagonist/mu agonist activities.
Organic Chemistry Department, Southern Research Institute, Birmingham, Alabama 35255, USA. ananthan@sri.org
S
S
Ananthan
C A
CA
Johnson
R L
RL
Carter
S D
SD
Clayton
K C
KC
Rice
H
H
Xu
P
P
Davis
F
F
Porreca
R B
RB
Rothman
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D006168:Guinea Pigs; D007082:Ileum / Q000187:drug effects / Q000502:physiology; D007211:Indoles / Q000138:chemical synthesis / Q000494:pharmacology; D008024:Ligands; D008297:Male; D051379:Mice; D009019:Morphinans / Q000138:chemical synthesis / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology; D051381:Rats; D011957:Receptors, Opioid / Q000819:agonists / Q000378:metabolism*; D017465:Receptors, Opioid, delta / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D013329:Structure-Activity Relationship; D014649:Vas Deferens / Q000187:drug effects / Q000502:physiology
C113354:17-(cyclopropylmethyl)-6,7-didehydro--13,14-dihydroxy-5'-(2-(2-pyridinyl)ethenyl)indolo(2',3'-6,7)morphinan; C113353:17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-13,14-dihydroxy-7'-phenoxyindolo(2',3'-6,7)morphinan; D007211:Indoles; D008024:Ligands; D009019:Morphinans; D009292:Narcotic Antagonists; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D009271:Naltrexone; C055382:naltrindole